Atazanavir clinical trials
Also written Reyataz and BMS-232632.
Counted the way a researcher would: Atazanavir with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses atazanavir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the atazanavir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 20 Jun 2003 · REYATAZ · NDA 021567 (FDA, Drugs@FDA)
- European Union
- 1 Mar 2004 · Reyataz · EMEA/H/C/000494 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
115 studies that test it; most in 2006 (14)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 3 |
| 2002 | 3 |
| 2003 | 1 |
| 2004 | 9 |
| 2005 | 13 |
| 2006 | 14 |
| 2007 | 8 |
| 2008 | 6 |
| 2009 | 14 |
| 2010 | 4 |
| 2011 | 9 |
| 2012 | 8 |
| 2013 | 3 |
| 2014 | 8 |
| 2015 | 5 |
| 2016 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 54 · Other 62
Bristol-Myers Squibb (35) · Gilead Sciences (7) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Radboud University Medical Center (4) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (4) · ViiV Healthcare (3) · ANRS, Emerging Infectious Diseases (2) · French National Agency for Research on AIDS and Viral Hepatitis (2)
Often tested with
Tested in the same studies.
Ritonavir (50) · Tenofovir (12) · Darunavir (9) · Efavirenz (9) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (9) · Cobicistat (8) · Emtricitabine (8) · Raltegravir (7)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test atazanavir.
Studies
Open first, then newest update. How each study uses atazanavir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 116
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingPhase 4Gilead SciencesNCT06337032Written as ATVHow we know
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVActive, not recruitingPhase 2/3Gilead SciencesNCT02016924Written as ATVHow we know
- Early and Intermittent Antiretroviral Therapy in Naive HIV Infected AdultsCompletedPhase 2ANRS, Emerging Infectious DiseasesNCT00820118Written as Structured treatment interruptionHow we know
- Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and TruvadaCompletedPhase 2French National Agency for Research on AIDS and Viral HepatitisNCT00528060Written as AtazanavirHow we know
- Antiviral Agents Against COVID-19 InfectionCompletedPhase 2/3Hospital do CoracaoNCT04468087Written as AtazanavirHow we know
- A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable ViremiaCompletedPhase 2Castagna AntonellaNCT02542852Written as atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mgHow we know
- Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral SuppressionCompletedPhase 3IRCCS San RaffaeleNCT01511809Written as Atazanavir/ritonavir monotherapyHow we know
- Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI BackboneWithdrawnPhase 3Bristol-Myers SquibbNCT01605084Written as AtazanavirHow we know
- A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed ConditionsCompletedPhase 1Bristol-Myers SquibbNCT05236738Written as AtazanavirHow we know
- The Nitazoxanide Plus Atazanavir for COVID-19 StudyTerminatedPhase 2Obafemi Awolowo UniversityNCT04459286Written as Nitazoxanide and atazanavir/ritonavirHow we know
- Taste Properties of Atazanavir and CobicistatCompletedPhase 1Bristol-Myers SquibbNCT02307656Written as AtazanavirHow we know
- Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected ChildrenCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00260078Written as AtazanavirHow we know
- Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and AdolescentsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00006604Written as ATVHow we know
- Preventing Sexual Transmission of HIV With Anti-HIV DrugsCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT00074581Written as AtazanavirHow we know
- Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected AdultsCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00096850Written as AtazanavirHow we know
- Atazanavir/Ritonavir Maintenance TherapyCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00084019Written as AtazanavirHow we know
- Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected AdultsCompletedPhase 3Gilead SciencesNCT02603107Written as ATVHow we know
- A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/CobicistatCompletedPhase 1Radboud University Medical CenterNCT02565888Written as AtazanavirHow we know
- Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance RegimenTerminatedPhase 2Radboud University Medical CenterNCT02566707Written as AtazanavirHow we know
- Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected PatientsCompletedPhase 2Radboud University Medical CenterNCT00943540Written as atazanavirHow we know
See all 116 studies that test atazanavir →
Given beside what is tested · 14 — atazanavir is usual care or a partner of the new treatment
- Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TCTerminatedPhase 3Bristol-Myers SquibbNCT01620944Written as AtazanavirHow we know
- Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat TrialsCompletedPhase 1Acrotech Biopharma Inc.NCT04184869Written as AtazanavirHow we know
- Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric PatientsCompletedPhase 3Bristol-Myers SquibbNCT01335698Written as Atazanavir SulphateHow we know
- Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced AdultsTerminatedPhase 2ViiV HealthcareNCT02386098Written as Atazanavir (ATV)How we know
- RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected PatientsStatus unknownPhase 4Pedro CahnNCT01829802Written as Ritonavir boosted AtazanavirHow we know
- Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedPhase 3Gilead SciencesNCT01108510Written as ATVHow we know
- Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal ImpairmentCompletedPhase 3Gilead SciencesNCT01363011Written as ATVHow we know
- Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedPhase 2Gilead SciencesNCT00892437Written as ATVHow we know
- Pilot Study of a Raltegravir Based NRTI Sparing RegimenCompletedNot applicableYale UniversityNCT00814879Written as AtazanavirHow we know
- PK TDF in Thai HIV-infected ChildrenCompletedNot applicableThe HIV Netherlands Australia Thailand Research CollaborationNCT02404259Written as lopinavir/ritonavir, atazanavir/ritonavirHow we know
- Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected PatientsCompletedPhase 4Bristol-Myers SquibbNCT01332227Written as AtazanavirHow we know
- Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02257008Written as AtazanavirHow we know
- Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.CompletedPhase 1/2Gilead SciencesNCT01565889Written as ATVHow we know
- Phase IIB Pilot of Atazanavir + RaltegravirTerminatedPhase 2Bristol-Myers SquibbNCT00768989Written as AtazanavirHow we know
As the comparator · 9 — what is tested is compared with atazanavir
- Safety & Efficacy of Dual Therapy With Raltegravir/LamivudineCompletedPhase 3Juan A. ArnaizNCT02284035Written as ATV/r plus ABC/3TCHow we know
- A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)CompletedPhase 3ViiV HealthcareNCT01910402Written as AtazanavirHow we know
- NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 InfectionStatus unknownPhase 2/3Biomed Industries, Inc.NCT04452565Written as NA-831 and AtazanavirHow we know
- Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsCompletedPhase 3Gilead SciencesNCT01815736Written as ATVHow we know
- Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected WomenCompletedPhase 3Gilead SciencesNCT02652624Written as ATVHow we know
- Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)TerminatedPhase 2Merck Sharp & Dohme LLCNCT02116660Written as AtazanavirHow we know
- HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) InfectionsCompletedPhase 2ViiV HealthcareNCT01384734Written as Atazanavir 300 mgHow we know
- Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsCompletedPhase 3Gilead SciencesNCT01106586Written as ATVHow we know
- Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive AdultsCompletedPhase 3Boehringer IngelheimNCT00389207Written as atazanavirHow we know
Codes
What other systems call atazanavir · ClinicalTrials.gg INT006580
- MeSH (NLM) D000069446Atazanavir SulfateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) QZU4H47A3SATAZANAVIRConfirmed FDA, NLM, Wikidata
- RxNorm 343047Confirmed FDA, Wikidata
- Wikidata Q423467atazanavirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66872AtazanavirOne source FDA
- DrugBank DB01072One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069446 | Atazanavir Sulfate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | QZU4H47A3S | ATAZANAVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 343047 | — | Confirmed FDA, Wikidata |
| Wikidata | Q423467 | atazanavir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66872 | Atazanavir | One source FDA |
| DrugBank | DB01072 | — | One source Wikidata |
Also registered as atazanavir sulfate (UNII 4MT4VIE29P · RxNorm 358299).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.